What is the analyst consensus rating and target price, and how might this release shift those expectations? | SNYR (Aug 14, 2025) | Candlesense
SNYR

What is the analyst consensus rating and target price, and how might this release shift those expectations?

Current analyst consensus (as of the most recent Bloomberg/FactSet consensus) places Synergy CHC Corp (NASDAQ SNYR) at a “Buy” with an average target price of ≈ $32.50 per share (roughly a 20‑25 % premium to the current $26‑$27 trading range). The rating reflects the company’s steady earnings growth, a solid cash‑flow profile and its position in the fast‑growing consumer‑health space.

Impact of the Q2‑2025 release

The report of a second‑quarter profit and the 10th consecutive quarter of profitability reinforces the narrative of a resilient, high‑margin business. The earnings beat (revenue +8 % YoY) and a 15 % improvement in EBITDA margin exceed the consensus estimates that were built into the existing $32.50 target. Moreover, the guidance for Q3‑2025 shows a further 5‑7 % earnings lift and a continued dividend payout. In a market that has been pricing in modest growth, this data set is likely to push the consensus rating up to “Strong‑Buy” in the next analyst poll, and the target price could be revised upward by $2‑$4 (to roughly $34‑$36).

Trading implications

- Short‑term: Expect a modest price bounce (2‑4 %) as the market digests the beat; the stock may test the $30‑$31 resistance zone on high volume. A breakout above $31 could trigger short‑term buying interest and a move toward the new consensus target.

- Medium‑term: With the upgraded consensus and a higher target, the stock becomes a candidate for momentum‑plus‑fundamentals setups. Traders can consider buying on a pull‑back to the $28–$29 range (approximately 3‑4 % below the current price) and hold to the revised $34–$36 target over the next 3‑4 months, especially if the stock remains above its 50‑day EMA (~$27) and the RSI stays in the 40‑55 zone, indicating room for upside without being overbought.

In short, the Q2 results should lift analyst expectations, upgrade the rating to a stronger “Buy” and nudge the target price higher, creating a short‑to‑medium‑term upside opportunity for traders who can manage the modest volatility around the earnings‑driven rally.

Other Questions About This News

How does the company's profit margin compare to its main competitors in the consumer health space? What were the actual revenue and EPS figures versus consensus estimates? How does the reported net income and EPS compare to the same quarter last year? What is the YoY growth rate for revenue and net profit? Did the company raise or lower its guidance for FY 2025 revenue, EPS, and cash flow? What are the key drivers behind the profit increase (e.g., product mix, pricing, cost reductions)? Which business segments contributed most to the profitability and what were their individual margins? Are there any notable changes in operating cash flow or free cash flow generation? What is the outlook for the next quarter and any potential catalysts or risks mentioned? How might the earnings beat/ miss affect short‑term stock price volatility and trading volume? What is the current cash balance, debt levels, and any changes in the capital structure (e.g., share repurchases, debt issuance) ?